Statin therapy and multiple sclerosis disability in a population-based cohort

M. Mateo Paz Soldán, Sean J Pittock, Stephen D. Weigand, Barbara P. Yawn, Moses Rodriguez

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Axonal damage and inflammatory demyelination both occur in multiple sclerosis (MS). Some studies suggest that statins, through pleiotropic effects, reduce inflammatory episodes and protect neurons. However, other studies suggest statins have disparate impacts on these pathologic processes. Objective: The objective of this study was to assess disability progression in MS patients receiving statin therapy. Methods: We performed a retrospective medical record review of an established population-based MS prevalence cohort in Olmsted County, Minnesota, comparing disability progression between patients receiving statins and controls. Results: Duration of statin use ranged from 1.9 to 20.3 years with a mean and standard deviation of 6.8 ± 4 years. Years between assessments ranged from 0.6 to 8.2 (75% of patients having intervals >6.4 years). The median (interquartile range) absolute change of disability among the statin group was 0 (0 to +1), compared with +0.5 (0, +1) in the no-statin group. Distributions were not significantly different (p = 0.39). The mean (standard deviation) absolute change of disability scores among the statin group was +0.69 (+1.49), not significantly different from +0.61 (+1.31) in the no-statin group. Likewise, annualized disability scores did not differ significantly (p = 0.23). Eighteen (40%) patients worsened by 1.0 or more on Expanded Disability Status Scale (EDSS) in the statin group and 36 (40%) in the no-statin group (p = 0.85, chi-squared test). Conclusions: In this cohort, disability progression did not differ between those receiving statin therapy and controls. These findings support the hypothesis that statins, in doses currently prescribed for hyperlipidemia, do not affect the long-term course of MS.

Original languageEnglish (US)
Pages (from-to)358-363
Number of pages6
JournalMultiple Sclerosis
Volume18
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Multiple Sclerosis
Population
Therapeutics
Demyelinating Diseases
Pathologic Processes
Hyperlipidemias
Medical Records

Keywords

  • disability
  • HMG-CoA reductase inhibitors
  • multiple sclerosis
  • population based
  • statins

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Statin therapy and multiple sclerosis disability in a population-based cohort. / Soldán, M. Mateo Paz; Pittock, Sean J; Weigand, Stephen D.; Yawn, Barbara P.; Rodriguez, Moses.

In: Multiple Sclerosis, Vol. 18, No. 3, 03.2012, p. 358-363.

Research output: Contribution to journalArticle

Soldán, M. Mateo Paz ; Pittock, Sean J ; Weigand, Stephen D. ; Yawn, Barbara P. ; Rodriguez, Moses. / Statin therapy and multiple sclerosis disability in a population-based cohort. In: Multiple Sclerosis. 2012 ; Vol. 18, No. 3. pp. 358-363.
@article{53fedd9a2de043e9b5fb4f1e06dca0ca,
title = "Statin therapy and multiple sclerosis disability in a population-based cohort",
abstract = "Background: Axonal damage and inflammatory demyelination both occur in multiple sclerosis (MS). Some studies suggest that statins, through pleiotropic effects, reduce inflammatory episodes and protect neurons. However, other studies suggest statins have disparate impacts on these pathologic processes. Objective: The objective of this study was to assess disability progression in MS patients receiving statin therapy. Methods: We performed a retrospective medical record review of an established population-based MS prevalence cohort in Olmsted County, Minnesota, comparing disability progression between patients receiving statins and controls. Results: Duration of statin use ranged from 1.9 to 20.3 years with a mean and standard deviation of 6.8 ± 4 years. Years between assessments ranged from 0.6 to 8.2 (75{\%} of patients having intervals >6.4 years). The median (interquartile range) absolute change of disability among the statin group was 0 (0 to +1), compared with +0.5 (0, +1) in the no-statin group. Distributions were not significantly different (p = 0.39). The mean (standard deviation) absolute change of disability scores among the statin group was +0.69 (+1.49), not significantly different from +0.61 (+1.31) in the no-statin group. Likewise, annualized disability scores did not differ significantly (p = 0.23). Eighteen (40{\%}) patients worsened by 1.0 or more on Expanded Disability Status Scale (EDSS) in the statin group and 36 (40{\%}) in the no-statin group (p = 0.85, chi-squared test). Conclusions: In this cohort, disability progression did not differ between those receiving statin therapy and controls. These findings support the hypothesis that statins, in doses currently prescribed for hyperlipidemia, do not affect the long-term course of MS.",
keywords = "disability, HMG-CoA reductase inhibitors, multiple sclerosis, population based, statins",
author = "Sold{\'a}n, {M. Mateo Paz} and Pittock, {Sean J} and Weigand, {Stephen D.} and Yawn, {Barbara P.} and Moses Rodriguez",
year = "2012",
month = "3",
doi = "10.1177/1352458511421920",
language = "English (US)",
volume = "18",
pages = "358--363",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Statin therapy and multiple sclerosis disability in a population-based cohort

AU - Soldán, M. Mateo Paz

AU - Pittock, Sean J

AU - Weigand, Stephen D.

AU - Yawn, Barbara P.

AU - Rodriguez, Moses

PY - 2012/3

Y1 - 2012/3

N2 - Background: Axonal damage and inflammatory demyelination both occur in multiple sclerosis (MS). Some studies suggest that statins, through pleiotropic effects, reduce inflammatory episodes and protect neurons. However, other studies suggest statins have disparate impacts on these pathologic processes. Objective: The objective of this study was to assess disability progression in MS patients receiving statin therapy. Methods: We performed a retrospective medical record review of an established population-based MS prevalence cohort in Olmsted County, Minnesota, comparing disability progression between patients receiving statins and controls. Results: Duration of statin use ranged from 1.9 to 20.3 years with a mean and standard deviation of 6.8 ± 4 years. Years between assessments ranged from 0.6 to 8.2 (75% of patients having intervals >6.4 years). The median (interquartile range) absolute change of disability among the statin group was 0 (0 to +1), compared with +0.5 (0, +1) in the no-statin group. Distributions were not significantly different (p = 0.39). The mean (standard deviation) absolute change of disability scores among the statin group was +0.69 (+1.49), not significantly different from +0.61 (+1.31) in the no-statin group. Likewise, annualized disability scores did not differ significantly (p = 0.23). Eighteen (40%) patients worsened by 1.0 or more on Expanded Disability Status Scale (EDSS) in the statin group and 36 (40%) in the no-statin group (p = 0.85, chi-squared test). Conclusions: In this cohort, disability progression did not differ between those receiving statin therapy and controls. These findings support the hypothesis that statins, in doses currently prescribed for hyperlipidemia, do not affect the long-term course of MS.

AB - Background: Axonal damage and inflammatory demyelination both occur in multiple sclerosis (MS). Some studies suggest that statins, through pleiotropic effects, reduce inflammatory episodes and protect neurons. However, other studies suggest statins have disparate impacts on these pathologic processes. Objective: The objective of this study was to assess disability progression in MS patients receiving statin therapy. Methods: We performed a retrospective medical record review of an established population-based MS prevalence cohort in Olmsted County, Minnesota, comparing disability progression between patients receiving statins and controls. Results: Duration of statin use ranged from 1.9 to 20.3 years with a mean and standard deviation of 6.8 ± 4 years. Years between assessments ranged from 0.6 to 8.2 (75% of patients having intervals >6.4 years). The median (interquartile range) absolute change of disability among the statin group was 0 (0 to +1), compared with +0.5 (0, +1) in the no-statin group. Distributions were not significantly different (p = 0.39). The mean (standard deviation) absolute change of disability scores among the statin group was +0.69 (+1.49), not significantly different from +0.61 (+1.31) in the no-statin group. Likewise, annualized disability scores did not differ significantly (p = 0.23). Eighteen (40%) patients worsened by 1.0 or more on Expanded Disability Status Scale (EDSS) in the statin group and 36 (40%) in the no-statin group (p = 0.85, chi-squared test). Conclusions: In this cohort, disability progression did not differ between those receiving statin therapy and controls. These findings support the hypothesis that statins, in doses currently prescribed for hyperlipidemia, do not affect the long-term course of MS.

KW - disability

KW - HMG-CoA reductase inhibitors

KW - multiple sclerosis

KW - population based

KW - statins

UR - http://www.scopus.com/inward/record.url?scp=84857880414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857880414&partnerID=8YFLogxK

U2 - 10.1177/1352458511421920

DO - 10.1177/1352458511421920

M3 - Article

VL - 18

SP - 358

EP - 363

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 3

ER -